Vormann M, Gijzen L, Hutter S, Boot L, Nicolas A, van den Heuvel A, et al. Nephrotoxicity and Kidney Transport Assessment on 3D Perfused Proximal Tubules. AAPS J. 2018;20:90 pubmed publisher

Storck S, Hartz A, Bernard J, Wolf A, Kachlmeier A, Mahringer A, et al. The concerted amyloid-beta clearance of LRP1 and ABCB1/P-gp across the blood-brain barrier is linked by PICALM. Brain Behav Immun. 2018;73:21-33 pubmed publisher

Dugardin C, Briand O, Touche V, Schonewille M, Moreau F, Le May C, et al. Retrograde cholesterol transport in the human Caco-2/TC7 cell line: a model to study trans-intestinal cholesterol excretion in atherogenic and diabetic dyslipidemia. Acta Diabetol. 2017;54:191-199 pubmed publisher

Georges E, Lian J, Laberge R. A tamoxifen derivative, N,N-diethyl-2-[4-(phenylmethyl) phenoxy] ethanamine, selectively targets P-glycoprotein-positive multidrug resistant Chinese hamster cells. Biochem Pharmacol. 2014;90:107-14 pubmed publisher

Brayboy L, Oulhen N, Witmyer J, Robins J, Carson S, Wessel G. Multidrug-resistant transport activity protects oocytes from chemotherapeutic agents and changes during oocyte maturation. Fertil Steril. 2013;100:1428-35 pubmed publisher

Lee W, Chakraborty P, Thevenod F. Pituitary homeobox 2 (PITX2) protects renal cancer cell lines against doxorubicin toxicity by transcriptional activation of the multidrug transporter ABCB1. Int J Cancer. 2013;133:556-67 pubmed publisher

Morad S, Messner M, Levin J, Abdelmageed N, Park H, Merrill A, et al. Potential role of acid ceramidase in conversion of cytostatic to cytotoxic end-point in pancreatic cancer cells. Cancer Chemother Pharmacol. 2013;71:635-45 pubmed publisher

Nagao K, Maeda M, Mañucat N, Ueda K. Cyclosporine A and PSC833 inhibit ABCA1 function via direct binding. Biochim Biophys Acta. 2013;1831:398-406 pubmed publisher

Bajelan E, Haeri A, Vali A, Ostad S, Dadashzadeh S. Co-delivery of doxorubicin and PSC 833 (Valspodar) by stealth nanoliposomes for efficient overcoming of multidrug resistance. J Pharm Pharm Sci. 2012;15:568-82 pubmed

Eadie L, Saunders V, Hughes T, White D. Degree of kinase inhibition achieved in vitro by imatinib and nilotinib is decreased by high levels of ABCB1 but not ABCG2. Leuk Lymphoma. 2013;54:569-78 pubmed publisher

Okyar A, Dressler C, Hanafy A, Baktir G, Lemmer B, Spahn Langguth H. Circadian variations in exsorptive transport: in situ intestinal perfusion data and in vivo relevance. Chronobiol Int. 2012;29:443-53 pubmed publisher

Binkhathlan Z, Shayeganpour A, Brocks D, Lavasanifar A. Encapsulation of P-glycoprotein inhibitors by polymeric micelles can reduce their pharmacokinetic interactions with doxorubicin. Eur J Pharm Biopharm. 2012;81:142-8 pubmed publisher

Binkhathlan Z, Elhasi S, Brocks D, Lavasanifar A. Characterization of the self assembly of methoxy poly(ethylene oxide)-block-poly(?-benzyl carboxylate-?-caprolactone) for the solubilization and in vivo delivery of valspodar. Curr Drug Deliv. 2012;9:164-71 pubmed

Crowe A. The role of P-glycoprotein and breast cancer resistance protein (BCRP) in bacterial attachment to human gastrointestinal cells. J Crohns Colitis. 2011;5:531-42 pubmed publisher

Kurihara H, Sato T, Akimoto N, Ogura T, Ito A. Identification and characterization of ABCB1-mediated and non-apoptotic sebum secretion in differentiated hamster sebocytes. Biochim Biophys Acta. 2011;1811:1090-6 pubmed publisher

Sziráki I, Erdo F, Beéry E, Molnár P, Fazakas C, Wilhelm I, et al. Quinidine as an ABCB1 probe for testing drug interactions at the blood-brain barrier: an in vitro in vivo correlation study. J Biomol Screen. 2011;16:886-94 pubmed publisher

Kuemmerle A, Yan H, Krueger T, Buclin T, Braissant O, Henry H, et al. P-glycoprotein modulation by valspodar and cyclosporin does not increase tumor uptake of doxorubicin administered via isolated lung perfusion to rats bearing sarcoma lung metastases. Anticancer Res. 2011;31:2121-8 pubmed

Mariana B, Adrián L, Guillermo V, Juan S, Laura M, Carlos L. Gender-related differences on P-glycoprotein-mediated drug intestinal transport in rats. J Pharm Pharmacol. 2011;63:619-26 pubmed publisher

Emmink B, van Houdt W, Vries R, Hoogwater F, Govaert K, Verheem A, et al. Differentiated human colorectal cancer cells protect tumor-initiating cells from irinotecan. Gastroenterology. 2011;141:269-78 pubmed publisher

Lee W, Torchalski B, Kohistani N, Thevenod F. ABCB1 protects kidney proximal tubule cells against cadmium-induced apoptosis: roles of cadmium and ceramide transport. Toxicol Sci. 2011;121:343-56 pubmed publisher

Aouali N, El Btaouri H, Dumontet C, Eddabra L, Malagarie Cazenave S, Madoulet C, et al. Accumulation of lactosylceramide and overexpression of a PSC833-resistant P-glycoprotein in multidrug-resistant human sarcoma cells. Oncol Rep. 2011;25:1161-7 pubmed publisher

Waterkotte B, Hambruch N, Doring B, Geyer J, Tinneberg H, Pfarrer C. P-glycoprotein is functionally expressed in the placenta-derived bovine caruncular epithelial cell line 1 (BCEC-1). Placenta. 2011;32:146-52 pubmed publisher

Jin L, Li J, Nation R, Nicolazzo J. Impact of p-glycoprotein inhibition and lipopolysaccharide administration on blood-brain barrier transport of colistin in mice. Antimicrob Agents Chemother. 2011;55:502-7 pubmed publisher

Robey R, Lin B, Qiu J, Chan L, Bates S. Rapid detection of ABC transporter interaction: potential utility in pharmacology. J Pharmacol Toxicol Methods. 2011;63:217-22 pubmed publisher

Smith N, Mani S, Schuetz E, Yasuda K, Sissung T, Bates S, et al. Induction of CYP3A4 by vinblastine: Role of the nuclear receptor NR1I2. Ann Pharmacother. 2010;44:1709-17 pubmed publisher

MacLean C, Moenning U, Reichel A, Fricker G. Regional absorption of fexofenadine in rat intestine. Eur J Pharm Sci. 2010;41:670-4 pubmed publisher

Kolitz J, George S, Marcucci G, Vij R, Powell B, Allen S, et al. P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. Blood. 2010;116:1413-21 pubmed publisher

Binkhathlan Z, Hamdy D, Brocks D, Lavasanifar A. Development of a polymeric micellar formulation for valspodar and assessment of its pharmacokinetics in rat. Eur J Pharm Biopharm. 2010;75:90-5 pubmed publisher

O Brien M, Lacayo N, Lum B, Kshirsagar S, Buck S, Ravindranath Y, et al. Phase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2010;54:694-702 pubmed publisher

Tai H. Technology evaluation: Valspodar, Novartis AG. Curr Opin Mol Ther. 2000;2:459-67 pubmed

Berg D, Centrilla L, Halsey J, Silvester P, Jones B, Guynn K, et al. Overcoming multidrug resistance: valspodar as a paradigm for nursing care. Oncol Nurs Forum. 1999;26:711-20 pubmed